Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Clinical trial NCT04862663 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04862663
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Start date: 2021-05-10
Primary completion: 2027-11-01
Enrollment: 893

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.